[1]刘 洁.格列美脲联合沙格列汀对腹型肥胖糖尿病患者脂代谢指标及胰岛功能的影响[J].医学信息,2022,35(13):123-126.[doi:10.3969/j.issn.1006-1959.2022.13.028]
　LIU Jie.Effect of Glimepiride Combined with Saxagliptin on Lipid Metabolism Indexes and Islet Function in Patients with Abdominal Obesity Diabetes Mellitus[J].Medical Information,2022,35(13):123-126.[doi:10.3969/j.issn.1006-1959.2022.13.028]
点击复制

格列美脲联合沙格列汀对腹型肥胖糖尿病患者脂代谢指标及胰岛功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年13期
页码:
123-126
栏目:
论著
出版日期:
2022-07-01

文章信息/Info

Title:
Effect of Glimepiride Combined with Saxagliptin on Lipid Metabolism Indexes and Islet Function in Patients with Abdominal Obesity Diabetes Mellitus
文章编号:
1006-1959（2022）13-0123-04
作者:
刘 洁
（天津市第二医院内分泌科，天津 300000）
Author(s):
LIU Jie
(Department of Endocrinology,Tianjin Second Hospital,Tianjin 300000,China)
关键词:
腹型肥胖; 糖尿病; 格列美脲; 沙格列汀; 脂代谢; 胰岛功能
Keywords:
Abdominal obesity; Diabetes mellitus; Glimepiride; Saxagliptin; Lipid metabolism; Islet function
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2022.13.028
文献标志码:
A
摘要:
目的 研究格列美脲联合沙格列汀对腹型肥胖糖尿病患者脂代谢指标及胰岛功能的影响。方法 选取2020年7月-2021年5月天津市第二医院内分泌科收治的84例腹型肥胖糖尿病患者，按照随机数字表法分为对照组与观察组，各42例。对照组给予格列美脲治疗，观察组给予格列美脲联合沙格列汀治疗，比较两组血糖水平[空腹血糖（FBG）、餐后2h血糖（PBG）、糖化血红蛋白（HbA1c）]、脂代谢指标[三酰甘油（TG）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）]、胰岛功能[空腹胰岛素（FINS）、胰岛素抵抗指数（HOMA-IR）、胰岛素分泌指数（HOMA-β）]、BMI及腰臀比。结果 两组治疗后FBG、PBG、HbA1c水平低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组治疗后TG、TC、LDL-C水平低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组治疗后FINS、HOMA-β高于治疗前，HOMA-IR低于治疗前，且观察组FINS、HOMA-β高于对照组，HOMA-IR低于对照组，差异有统计学意义（P＜0.05）；两组治疗后BMI、腰臀比低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）。结论 格列美脲联合沙格列汀对腹型肥胖糖尿病患者的降糖效果确切，可调节脂代谢指标，改善胰岛功能，促进患者体重指数及腰臀比的下降。
Abstract:
Objective To study the effect of glimepiride combined with saxagliptin on lipid metabolism indexes and islet function in patients with abdominal obesity diabetes mellitus.Methods A total of 84 patients with abdominal obesity diabetes mellitus admitted to the Department of Endocrinology of Tianjin Second Hospital from July 2020 to May 2021 were selected and randomly divided into control group and observation group, with 42 cases in each group. The control group was treated with glimepiride, and the observation group was treated with glimepiride combined with saxagliptin. The blood glucose levels [fasting blood glucose (FBG), postprandial 2 h blood glucose (PBG), glycosylated hemoglobin (HbA1c)], lipid metabolism indexes [triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C)], islet function [fasting insulin (FINS), insulin resistance index (HOMA-IR), insulin secretion index (HOMA-β)], BMI and waist hip ratio were compared between the two groups.Results After treatment, the levels of FBG, PBG and HbA1c in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05); the levels of TG, TC and LDL-C in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05); FINS and HOMA-β in the two groups were higher than those before treatment, HOMA-IR was lower than that before treatment, FINS and HOMA-β in the observation group were higher than those in the control group, HOMA-IR was lower than that in the control group, the difference was statistically significant (P<0.05); BMI and waist-hip ratio in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05).Conclusion Glimepiride combined with saxagliptin has definite hypoglycemic effect on patients with abdominal obesity and diabetes, which can regulate lipid metabolism indexes, improve islet function, and promote the decrease of body mass index and waist-hip ratio.

参考文献/References:

[1]苏志宇,郭燕芬,肖美华.格列美脲联合利格列汀治疗2型糖尿病合并肥胖患者的临床价值分析[J].中国处方药,2021,19(7):124-125.[2]李超杰,陈慧敏,濮先明.利拉鲁肽、格列美脲分别联用二甲双胍治疗肥胖型2型糖尿病疗效观察[J].陕西医学杂志,2021,50(3):356-358,373.[3]Leitner DR,Frühbeck G,Yumuk V,et al.Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way[J].Obes Facts,2017,10(5):483-492.[4]王乐,赵文婷.盐酸吡格列酮联合格列美脲治疗肥胖2型糖尿病患者的临床效果观察[J].中国医药,2016,11(11):1649-1652.[5]范晓霞,姚勇利,胡耀嘉,等.超重和肥胖2型糖尿病伴微量白蛋白尿患者使用达格列净或沙格列汀控制血糖疗效和安全性的观察[J].中国糖尿病杂志,2020,28(2):85-88.[6]卓雅芬,孙志纯.沙格列汀与利拉鲁肽治疗初发肥胖型2型糖尿病的效果[J].中外医学研究,2019,17(35):54-56.[7]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398.[8]Boles A,Kandimalla R,Reddy PH.Dynamics of diabetes and obesity: Epidemiological perspective[J].Biochim Biophys Acta Mol Basis Dis,2017,1863(5):1026-1036.[9]冯会芳,万明,孙秋.沙格列汀联合利拉鲁肽对2型糖尿病肥胖患者胰岛功能及体重影响与安全性研究[J].中国临床医生杂志,2018,46(6):679-681.[10]庞淑梅.格列美脲治疗糖尿病伴肥胖患者的临床效果观察[J].临床合理用药杂志,2017,10(11):40-41.[11]那日苏,刘志文,马聪,等.格列美脲联合沙格列汀治疗2型糖尿病的疗效观察[J].现代药物与临床,2018,33(10):2585-2588.[12]云新蕾.格列美脲联合利格列汀对2型糖尿病合并肥胖患者血糖控制及体质指数变化的影响[J].实用糖尿病杂志,2018,14(2):25-26.[13]张建宏.沙格列汀对行短期胰岛素泵强化治疗的初诊肥胖2型糖尿病患者血糖波动、胰岛功能影响研究[J].黑龙江中医药,2021,50(3):447-448.[14]白贞贞.沙格列汀对2型糖尿病伴正常体重的代谢性肥胖患者胰岛素抵抗及体脂成分的影响[J].国际医药卫生导报,2018,24(4):576-578.[15]郭迎霞,邱正伦.格列美脲联合利格列汀对2型糖尿病合并肥胖患者血糖控制及体质量指数变化的影响[J].药品评价,2018,15(11):15-17.[16]张丰姣,何丽,李皓雲,等.格列美脲联合沙格列汀对2型糖尿病合并肥胖患者血糖控制及体质量指数的影响[J].中国地方病防治杂志,2017,32(8):918,921.[17]李影,高扬,曾瑛.老龄化引起的脂肪组织重新分布与代谢功能障碍[J].中国细胞生物学学报,2014,36(2):280-286.[18]刘静.格列美脲联合沙格列汀治疗2型糖尿病合并肥胖的效果及安全性观察[J].医学理论与实践,2019,32(9):1334-1335.[19]孙建.利拉鲁肽与沙格列汀治疗腹型肥胖2型糖尿病临床研究[J].中国现代医药杂志,2016,18(11):77-79.[20]邵爱萍.格列美脲联合利格列汀治疗2型糖尿病合并肥胖患者的临床效果[J].中国医药导报,2017,14(3):88-90,94.[21]Achari AE,Jain SK.Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction[J].Int J Mol Sci,2017,18(6):1321.[22]卢海德.肥胖型2型糖尿病患者联用奥利司他与沙格列汀、二甲双胍治疗的效果[J].黑龙江医药,2021,34(1):108-110.[23]廖霜.二甲双胍联合沙格列汀或格列美脲对新诊断合并腹型肥胖的2型糖尿病患者临床疗效对比[J].医学信息,2018,31(24):70-73.[24]Zhou J,Wang Y,He Y,et al.Non-obese type 2 diabetes patients present intestinal B cell dysregulations associated with hyperactive intestinal Tfh cells[J].Mol Immunol,2018,97:27-32.[25]陈超,邢学农,任安,等.沙格列汀对2型糖尿病伴正常体重的代谢性肥胖患者体脂成分的影响[J].中国糖尿病杂志,2016,24(8):693-696.

相似文献/References:

[1]张西园.糖尿病与结直肠癌患者预后相关研究进展[J].医学信息,2018,31(01):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
　ZHANG Xi-yuan.Research Progress in the Relationship between Diabetes and the Prognosis of Colorectal Cancer[J].Medical Information,2018,31(13):55.[doi:10.3969/j.issn.1006-1959.2018.01.020]
[2]耿金萍.综合护理对甲状腺良性肿瘤并糖尿病患者手术效果的影响分析[J].医学信息,2018,31(01):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
　GENG Jin-ping.Analysis of the Effect of Comprehensive Nursing on the Surgical Effect of Thyroid Benign Tumor and Diabetic Patients[J].Medical Information,2018,31(13):163.[doi:10.3969/j.issn.1006-1959.2018.01.064]
[3]李雯婷,谈世华,余江明,等.踝肱指数检测在住院糖尿病患者中的重复性研究[J].医学信息,2018,31(03):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
　LI Wen-ting,TAN Shi-hua,YU Jiang-ming,et al.Study on Reproducibility of Ankle-brachial Index in Inpatients with Diabetes Mellitus[J].Medical Information,2018,31(13):159.[doi:10.3969/j.issn.1006-1959.2018.03.058]
[4]刘 静.冠状动脉粥样硬化性心脏病合并糖尿病的血脂检验结果分析[J].医学信息,2018,31(04):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
　LIU Jing.Analysis of Blood Lipid Test Results in Coronary Atherosclerotic Heart Disease Complicated with Diabetes Mellitus[J].Medical Information,2018,31(13):154.[doi:10.3969/j.issn.1006-1959.2018.04.057]
[5]谢勇丽,苏晓清,张雅薇.糖尿病痛性周围神经病变患者情绪调查分析[J].医学信息,2018,31(05):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
　XIE Yong-li,SU Xiao-qing,ZHANG Ya-wei.Investigation and Analysis of Mood in Patients with Diabetic Peripheral Neuropathy[J].Medical Information,2018,31(13):14.[doi:10.3969/j.issn.1006-1959.2018.05.005]
[6]张雅薇,朱明慧.首发为动眼神经麻痹的糖尿病合并动眼神经麻痹误诊为痛性眼肌麻痹1例分析[J].医学信息,2018,31(05):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
　ZHANG Ya-wei,ZHU Ming-hui.An Analysis of a Case of Diabetes Mellitus with Oculomotor Nerve Palsy Misdiagnosed as Painful Ophthalmoplegia[J].Medical Information,2018,31(13):23.[doi:10.3969/j.issn.1006-1959.2018.05.008]
[7]张宇宁.黄酮类化合物治疗糖尿病及其并发症的研究[J].医学信息,2018,31(05):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
　ZHANG Yu-ning.Study on Flavonoids in the Treatment of Diabetes Mellitus and its Complications[J].Medical Information,2018,31(13):50.[doi:10.3969/j.issn.1006-1959.2018.05.018]
[8]柳 梅.头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的 临床效果观察[J].医学信息,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
　LIU Mei.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection[J].Medical Information,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
[9]吕桂英.影响糖尿病患者药物治疗依从性相关因素临床分析[J].医学信息,2018,31(08):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
　LV Gui-ying.Clinical Analysis of Factors Related to Compliance with Drug Therapy in Patients with Diabetes Mellitus[J].Medical Information,2018,31(13):109.[doi:10.3969/j.issn.1006-1959.2018.08.036]
[10]刘爱君.糖化血红蛋白测定在糖尿病诊断中的应用价值分析[J].医学信息,2018,31(08):161.[doi:10.3969/j.issn.1006-1959.2018.08.057]
　LIU Ai-jun.Analysis of the Value of Determination of Glycosylated Hemoglobin in the Diagnosis of Diabetes Mellitus[J].Medical Information,2018,31(13):161.[doi:10.3969/j.issn.1006-1959.2018.08.057]

更新日期/Last Update: 1900-01-01